AXIM Biotechnologies (AXIM) 10-Q2023 Q2 Quarterly report

Filed: 21 Aug 23, 1:35pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: Abated, attention, attorney, begun, brain, broadly, Compensatory, Complaint, Conditionally, consequential, Conspiracy, defendant, Defraud, depth, dispersion, dispute, exemplary, FAC, fentanyl, Fraud, honour, Interference, IP, Kurty, lawsuit, lethality, matter, mesh, methodology, Micromesh, novelty, opioid, Phinney, Plaintiff, pleading, prevail, proposition, pterygium, Punitive, SAR, simultaneously, speed, Superior, synthetic, Theron, Trust, underlaying, Unjust, unrealized, vital

Removed: Abs, absence, adjusted, administering, aerosolized, affiliate, agent, algorithm, AlphaLisa, Assignee, ATD, background, beneficially, bind, biological, biomolecule, bound, breath, calibration, capture, capturing, cellular, Certification, Charter, chemical, chemotherapy, chloride, combined, companion, condensate, contemplating, Continuation, convalescent, curve, decoupling, dermal, Description, distinguishable, domain, downregulated, duly, ECS, Electrical, electrode, ELISA, embodiment, Engender, exhaled, Exhibit, facemask, factor, filtration, frequency, generation, Governance, handheld, HT, identification, imaginary, immune, impede, implementation, inactivating, incubated, Index, induce, inhibition, innate, interaction, introduce, Invented, kidney, knowledge, label, LFA, library, Linkbase, listing, logarithmically, mask, mixed, mixture, moiety, molecule, myeloma, neoplastic, neutralize, Nominating, Nonprovisional, Ointment, optimal, osmolality, overexpressing, page, parent, PCT, potent, proceeding, qualitatively, quantitatively, quantity, Ratio, RBD, receptor, Redeemable, referenced, salinity, saliva, scaffold, Schema, sequence, Serial, serology, shelf, shift, signal, signaling, signature, sodium, spike, sprayed, stable, structurally, subtraction, Super, suppressing, sweat, target, Taxonomy, termination, thereto, thereunto, throughput, topical, undersigned, varying, volving, wild, XBRL

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

AXIM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Axim Biotechnologies, Inc., a Nevada corporation, (the “Registrant”) on Form 10-Q for the Period ended June 30, 2023 (the “Report”), I, John W. Huemoeller II, Chief Executive Officer of the Registrant, do hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

	(1)	the Report, as filed with the Securities and Exchange Commission, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Dated: August 21, 2023

By:

/s/ John W. Huemoeller II

John W. Huemoeller II

Chief Executive Officer

(Principal Executive Officer)